Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuropathy Associated With Velcade Appears Reversible, Analysis Shows

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Peripheral neuropathy associated with Millennium’s Velcade appears to be reversible in most cases, according to an analysis presented at the American Society of Hematology annual meeting Dec. 9.

You may also be interested in...

Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal

Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.

Velcade "Impressive" Efficacy Offsets Concerns Over Response As Endpoint

"Impressive" and "better than expected" efficacy results with Millennium’s multiple myeloma agent Velcade were enough to outweigh FDA’s concerns about the use of response rate as a surrogate endpoint, NDA review documents indicate.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts